Last reviewed · How we verify
Ropivacaine Continuous Infusion Catheter
At a glance
| Generic name | Ropivacaine Continuous Infusion Catheter |
|---|---|
| Also known as | TAP block initiated with ropivacaine bolus and infusion |
| Sponsor | University of California, Davis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Patient-Titrated Automated Intermittent Boluses of Local Anesthetic vs. a Continuous Infusion Via a Perineural Catheter for Postoperative Analgesia (PHASE4)
- PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies (NA)
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Liposomal Bupivacaine vs Continuous Nerve Catheters for Below the Knee Amputations (PHASE4)
- Enhanced Recovery After Major Surgery and Chronic Pain for Total Knee Arthroplasty (NA)
- Randomized Study of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery (NA)
- Continuous Infusions vs Scheduled Bolus Infusions (PHASE4)
- Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: